Disease relevance of TASOSARTAN

• OBJECTIVE: Evaluate the effects of 2 weeks of treatment with tasosartan (1) on cardiac function at rest and during submaximal exercise, (2) on exercise peak oxygen uptake, and (3) on regional haemodynamics at rest in a control condition and during the recovery period of submaximal exercise in patients with essential hypertension [1].

High impact information on TASOSARTAN

• During submaximal exercise and during the recovery period after submaximal exercise, the reduced blood pressure found with tasosartan was associated with a reduced total peripheral resistance compared to placebo whereas cardiac output, heart rate, or stroke volume were not affected [1].
• CONCLUSIONS: The results of this study indicate that antagonism of the AT1 receptor with tasosartan reduces blood pressure at rest and during submaximal exercise but not during maximal exercise [1].
• RESULTS: At rest in the control condition, tasosartan significantly reduced blood pressure although total peripheral resistance, cardiac output and stroke volume as well as forearm and calf vascular resistances were not significantly affected compared to placebo [1].
• For area under the change in diastolic blood pressure curve, the reduction was significantly greater after tasosartan + atenolol compared with that after atenolol alone (336 +/- 85 and 190 +/- 71 mmHg.24 h; p < 0.05 for combination and atenolol alone, respectively; mean +/- SEM) [2].
• The relative receptor binding affinities of currently available AT1-receptor blockers is candesartan > irbesartan > valsartan/EXP-3174/telmisartan > tasosartan > losartan > eprosartan [3].

Chemical compound and disease context of TASOSARTAN

• A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension [2].

Associations of TASOSARTAN with other chemical compounds

• The additive effects of tasosartan and atenolol in decreasing diastolic blood pressure may provide a rationale for combination antihypertensive therapy [2].

Analytical, diagnostic and therapeutic context of TASOSARTAN

• AngII receptor blockade effect of single doses of tasosartan (100 mg p.o. and 50 mg i.v) and enoltasosartan (2.5 mg i.v.) were compared in 12 healthy subjects in a randomized, double blind, three-period crossover study using two approaches: the in vivo blood pressure response to exogenous AngII and an ex vivo AngII radioreceptor assay [4].
• CONCLUSIONS: These results demonstrate that tasosartan at 50 to 200 mg given once a day over a titration period of 10 weeks was effective and safe in the treatment of essential hypertension [5].

References